The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | KEYNOTE-177 & CheckMate 142: checkpoint blockade in MSI-H/dMMR CRC
Heinz-Josef Lenz, MD, FACP, University of Southern California, Los Angeles, CA, provides an update on the use of nivolumab and ipilimumab as first-line therapy in patients with microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) colorectal cancer (CRC), as evaluated in two recently published studies, KEYNOTE-177 (NCT02563002) and CheckMate 142 (NCT02060188). Prof. Lenz also explores the role of KRAS signaling in mediating an immune response associated with checkpoint blockade. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
